23
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Hepatitis C Genotypes in Hemophilia Patients in Iran

      letter
      1 , *
      Iranian Red Crescent Medical Journal
      Kowsar
      Hepatitis C, Genotype, Hemophilia, Iran

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Dear Editor, I genuinely enjoyed reading the excellent and informative original article by Keshvari and colleagues in your journal recently.[1] Patients with hemophilia are at greater risk for all forms of viral hepatitis, especially hepatitis C than other patients.[2] The prevalence of hepatitis C virus (HCV) infection in Iranian patients with hemophilia was from 15.6% in Fars to 76.7% in North-West of Iran.[3] Recently, a meta-analysis was done by Alavian et al. and demonstrated that the prevalence rate of HCV infection among Iranian hemophilic patients was almost 40.8%.[4] The HCV genotypes and subtypes should be determined before starting any treatment for HCV infection, as it determines the selection of a proper antiviral therapy, and the duration of treatment too.[5] According to the Keshvari et al. article,[1] the most frequent HCV genotype was 1a (58%), followed by genotype 3a (18.5%), genotype 1b (14.7%), and mixed HCV genotypes were detected in 6.2% of cases. These findings were compatible with previous studies in Iran.[6][7][8] The pattern of HCV genotypes in their patients was similar to Western Europe and different to Middle East countries, thus the author denotes to this pattern of HCV genotype in Iran due to probable use of clotting factors from Europe before 1987. In their study, there was no association between HCV genotypes and viral load, liver biochemical profiles, and splenomegaly although these findings were corresponded to other studies about this association. The sample size of study was high (367 hemophilic patients with clinically and laboratory proven chronic HCV infection), and complete information on subjects were reported including bleeding disorder types, demographic parameters, biochemical profile that were well summarized in the tables. There are some problems in design of some tables such as Table 1. It would be better that the title of each category (Bleeding disorder type, Bleeding severity, Laboratory parameters, HCV genotypes, Splenomegaly) to be distinguishable from their subcategory, but regarding Table 2 nd 3, they were good organized. However, these small problems cannot reduce the value of this article. As we evaluated the HCV genotypes in 8759 Iranian HCV infected patients (In Press), showing that subtype 1a was the most frequent one in patients less than 40 years (39% vs. 36.4%) and subtype 3a was the most frequent in patients older than 40 years (33% vs. 29.1%). It is better to analyze the HCV genotypes in hemophilia patients while considering the age too. Finally, I appreciate this absolutely perfect and informative article on genotyping of HCV in Iranian patients with hemophilia that can enhance and improve our knowledge about this disease in our country.

          Related collections

          Most cited references13

          • Record: found
          • Abstract: found
          • Article: not found

          Hepatitis C virus: virology, diagnosis and management of antiviral therapy.

          Hepatitis C virus (HCV) infects approximately 170 million individuals worldwide. Prevention of HCV infection complications is based on antiviral therapy with the combination of pegylated interferon alfa and ribavirin. The use of serological and virological tests has become essential in the management of HCV infection in order to diagnose infection, guide treatment decisions and assess the virological response to antiviral therapy. Anti-HCV antibody testing and HCV RNA testing are used to diagnose acute and chronic hepatitis C. The HCV genotype should be systematically determined before treatment, as it determines the indication, the duration of treatment, the dose of ribavirin and the virological monitoring procedure. HCV RNA monitoring during therapy is used to tailor treatment duration in HCV genotype 1 infection, and molecular assays are used to assess the end-of-treatment and, most importantly the sustained virological response, i.e. the endpoint of therapy.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Hepatitis C infection in Iran; A review article

            SM Alavian (2009)
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Distribution of hepatitis C virus genotypes in Iranian patients with congenital bleeding disorders

                Bookmark

                Author and article information

                Journal
                Iran Red Crescent Med J
                Iran Red Crescent Med J
                Kowsar
                Iranian Red Crescent Medical Journal
                Kowsar
                2074-1804
                2074-1812
                February 2011
                01 February 2011
                : 13
                : 2
                : 146-147
                Affiliations
                [1 ]Department of Virology, Tehran University of Medical Sciences, Tehran, Iran
                Author notes
                [* ]Correspondence: Farah Bokharaei-Salim, PhD, Department of Virology, Tehran University of Medical Sciences, Tehran, Iran. Tel.: +98-21-88715350, Fax: +98-21-88706555, E-mail: bokharaeifarah@ 123456gmail.com
                Article
                3371911
                22737452
                a05d75f2-be8f-425b-b954-9602e9c32201
                Copyright © 2011, Kowsar M.P. Co.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 10 September 2010
                : 13 December 2010
                : 06 December 2010
                Categories
                Letter to Editor

                Medicine
                genotype,hemophilia,hepatitis c,iran
                Medicine
                genotype, hemophilia, hepatitis c, iran

                Comments

                Comment on this article